Skybiotech Healthcare
Close ·
- P/E
- Not meaningful: loss-making over the last twelve months
Key Fundamentals
MicrocapTextilesConsumer DiscretionaryPrice-based figures at the close · EPS basis: Consolidated · TTM
- ROCE
- −9.32%
- Debt to Equity
- 1.05
- EPS (TTM)
- −₹8.68
- Book Value
- ₹41.74
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 2.76
- ROE
- −13.20%
- Dividend Yield
- 0.00%
- EBITDA
- −₹1.20 Cr
- 52W High
- ₹218.20
- 52W Low
- ₹113.70
Key Insights
No strengths listed
Weaknesses
4- Stock is trading at 2.79 times its book value
- Company has low interest coverage ratio.
- Company might be capitalizing the interest cost
- Debtor days have increased from 40.0 to 58.0 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 11 | 5 | 3 |
| Oscillators | Bullish | 1 | 5 | 3 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 28.17
- Bullish
- MACD (12,26,9)
- −2.13
- Bullish
- SMA (50)
- 122.97
- Bearish
- SMA (200)
- 158.33
- Bearish
As of
Growth Rate
From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 1Y | +0.43% |
|---|---|
| TTM | −30.94% |
Net profit
| 1Y | Loss narrowed by ₹1.25 Cr |
|---|---|
| TTM | Loss narrowed by ₹0.08 Cr |
Operating cash flow
| 1Y | Outflow widened by ₹0.48 Cr |
|---|---|
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 1Y | +11.16 pp |
|---|---|
| TTM | −22.93 pp |
Revenue by year
| Mar 2024 | ₹0.00 Cr |
|---|---|
| Mar 2025 | ₹6.96 Cr |
| Mar 2026 | ₹6.99 Cr |
Net profit by year
| Mar 2024 | ₹1.54 Cr |
|---|---|
| Mar 2025 | −₹2.37 Cr |
| Mar 2026 | −₹1.12 Cr |
Quarterly Results
₹ Cr| Particulars | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 1.6 | 2.52 | 1.02 | 2.39 | 1.92 | 0.96 | 1.83 | 0.49 |
| Expenses | 0.05 | 0.04 | 1.58 | 2.83 | 2.11 | 2.31 | 2.15 | 1.41 | 2.71 | 1.02 |
| Operating Profit | −0.05 | −0.04 | 0.02 | −0.31 | −1.09 | 0.08 | −0.23 | −0.45 | −0.88 | −0.53 |
| OPM % | — | — | 1.25% | −12.3% | −106.86% | 3.35% | −11.98% | −46.88% | −48.09% | −108.16% |
| Other Income | 1.37 | 0.35 | 0.04 | 0.15 | −0.18 | 0.03 | 0.04 | 0.08 | 0.15 | 0.06 |
| Interest | 0 | 0 | 0.13 | 0.11 | −0.23 | 0.01 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0.13 | 0.14 | 0.15 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 |
| PBT | 1.32 | 0.31 | −0.2 | −0.41 | −1.19 | −0.02 | −0.31 | −0.49 | −0.85 | −0.58 |
| Tax % | 18.94% | 19.35% | 30% | −4.88% | −8.4% | 0% | 0% | 0% | −64.71% | 0% |
| Net Profit | 1.07 | 0.25 | −0.25 | −0.39 | −1.08 | −0.02 | −0.31 | −0.48 | −0.3 | −0.57 |
| EPS (₹) | 5.59 | 1.31 | −1.31 | −2.04 | −5.64 | −0.1 | −1.62 | −2.51 | −1.57 | −2.98 |
Profit & Loss
₹ Cr| Particulars | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 0 | 6.96 | 6.99 | 5.2 |
| Expenses | 0.12 | 9.21 | 8.47 | 7.29 |
| Operating Profit | −0.12 | −2.25 | −1.48 | −2.09 |
| OPM % | — | −32.33% | −21.17% | −40.19% |
| Other Income | 2 | 0.38 | 0.31 | 0.33 |
| Interest | 0 | 0.01 | 0.02 | 0 |
| Depreciation | 0 | 0.54 | 0.48 | 0.47 |
| PBT | 1.88 | −2.42 | −1.67 | −2.23 |
| Tax % | 18.09% | −2.07% | −32.93% | — |
| Net Profit | 1.54 | −2.37 | −1.12 | −1.66 |
| EPS (₹) | 8.04 | −12.38 | −5.85 | −8.68 |
| Div. Payout % | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | — | 1.92 | 1.92 |
| Reserves | — | 7.07 | 6.08 |
| Borrowings | — | 7.2 | 8.42 |
| Other Liabilities | — | 3.91 | 3.02 |
| Total Liabilities | — | 20.1 | 19.44 |
| Fixed Assets | — | 12.03 | 11.55 |
| CWIP | — | 0 | 0 |
| Investments | — | 2.46 | 2.24 |
| Other Assets | — | 5.61 | 5.65 |
| Total Assets | — | 20.1 | 19.44 |
Cash Flow
₹ Cr| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | — | −1.04 | −1.52 |
| Investing | — | −9.63 | 0.02 |
| Financing | — | 1.24 | 1.17 |
| Net Cash Flow | — | −9.43 | −0.33 |
| Free Cash Flow | — | −1.37 | −1.52 |
| CFO/EBITDA | — | 46 | 103 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | — | 22.03 | 57.96 |
| Inventory Days | — | — | 356 |
| Days Payable | — | — | 378 |
| Cash Conversion Cycle | — | 22.03 | 35.71 |
| Working Capital Days | — | −27.27 | −1.57 |
| ROCE % | — | — | −9.32% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Skybiotech Healthcare insights
60 extracted metrics across FY01–FY27.
Documents
- General announcements 16 Oct 2026
Frequently Asked Questions about Skybiotech Healthcare
What does Skybiotech Healthcare Limited do?
Where is Skybiotech Healthcare Limited (SKYBIOTECH) listed?
Which sector does Skybiotech Healthcare Limited belong to?
What is the 52-week high and low of Skybiotech Healthcare Limited?
What is the Return on Equity (ROE) of Skybiotech Healthcare Limited?
Company Information
Incorporated in 1983, Skybiotech Healthcare Ltd is in the business of Textile and Pharmaceuticals
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/512036.md for Skybiotech Healthcare Limited: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.